$ZURA
Zura Bio Ltd

2024 Q4 Form 10-Q Financial Statement

#000141057824001779 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $13.29M
YoY Change 113.67%
% of Gross Profit
Research & Development $6.029M
YoY Change 52.06%
% of Gross Profit
Depreciation & Amortization $3.000K
YoY Change
% of Gross Profit
Operating Expenses $19.32M
YoY Change 89.64%
Operating Profit -$19.32M
YoY Change 89.64%
Interest Expense -$1.405M
YoY Change -173.18%
% of Operating Profit
Other Income/Expense, Net -$1.383M
YoY Change -172.14%
Pretax Income -$20.70M
YoY Change 150.33%
Income Tax
% Of Pretax Income
Net Earnings -$20.70M
YoY Change 149.42%
Net Earnings / Revenue
Basic Earnings Per Share -$0.26
Diluted Earnings Per Share -$0.26
COMMON SHARES
Basic Shares Outstanding 65.29M 87.34M
Diluted Shares Outstanding 87.34M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $188.2M
YoY Change 81.16%
Cash & Equivalents $188.2M
Short-Term Investments
Other Short-Term Assets $754.0K
YoY Change 7.71%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $189.0M
YoY Change 80.68%
LONG-TERM ASSETS
Property, Plant & Equipment $44.00K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $52.00K
YoY Change
Total Long-Term Assets $96.00K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $189.0M
Total Long-Term Assets $96.00K
Total Assets $189.1M
YoY Change 80.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.014M
YoY Change -38.36%
Accrued Expenses $16.65M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $18.24M
YoY Change 7.24%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.24M
Total Long-Term Liabilities $0.00
Total Liabilities $18.24M
YoY Change -3.79%
SHAREHOLDERS EQUITY
Retained Earnings -$142.3M
YoY Change 49.76%
Common Stock $7.000K
YoY Change 75.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $153.0M
YoY Change
Total Liabilities & Shareholders Equity $189.1M
YoY Change 80.77%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$20.70M
YoY Change 149.42%
Depreciation, Depletion And Amortization $3.000K
YoY Change
Cash From Operating Activities -$5.653M
YoY Change 119.96%
INVESTING ACTIVITIES
Capital Expenditures $13.00K
YoY Change -99.42%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$13.00K
YoY Change -99.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.444M
YoY Change -231.82%
NET CHANGE
Cash From Operating Activities -5.653M
Cash From Investing Activities -13.00K
Cash From Financing Activities 5.444M
Net Change In Cash -222.0K
YoY Change -97.52%
FREE CASH FLOW
Cash From Operating Activities -$5.653M
Capital Expenditures $13.00K
Free Cash Flow -$5.666M
YoY Change 17.55%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Entity Central Index Key
EntityCentralIndexKey
0001855644
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
zura Transfers Between Level2 And Level3
TransfersBetweenLevel2AndLevel3
0
CY2024Q3 zura Transfers Between Level2 And Level3
TransfersBetweenLevel2AndLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2024Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43593678
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
65293530
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40598
dei Entity Registrant Name
EntityRegistrantName
ZURA BIO LIMITED
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1725736
dei Entity Address Address Line1
EntityAddressAddressLine1
1489 W. Warm Springs Rd. #110
dei Entity Address City Or Town
EntityAddressCityOrTown
Henderson
dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89014
dei City Area Code
CityAreaCode
702
dei Local Phone Number
LocalPhoneNumber
825-9872
dei Security12b Title
Security12bTitle
Class A Ordinary Shares
dei Trading Symbol
TradingSymbol
ZURA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
65293530
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
188221000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
99806000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
754000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1037000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
188975000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
100843000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
44000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
52000
CY2024Q3 us-gaap Assets
Assets
189071000
CY2023Q4 us-gaap Assets
Assets
100843000
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
18244000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
20302000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
18244000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20302000
CY2023Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent
SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent
990000
CY2024Q3 us-gaap Liabilities
Liabilities
18244000
CY2023Q4 us-gaap Liabilities
Liabilities
21292000
CY2024Q3 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
16240000
CY2023Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
18680000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
65293530
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43593678
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
7000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
295311000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
162820000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-142272000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-103494000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
153046000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
59330000
CY2024Q3 us-gaap Minority Interest
MinorityInterest
1541000
CY2023Q4 us-gaap Minority Interest
MinorityInterest
1541000
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
154587000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
60871000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
189071000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
100843000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6029000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3965000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15161000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37079000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13290000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6222000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24296000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14732000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
19319000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
10187000
us-gaap Operating Expenses
OperatingExpenses
39457000
us-gaap Operating Expenses
OperatingExpenses
51811000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-19319000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10187000
us-gaap Operating Income Loss
OperatingIncomeLoss
-39457000
us-gaap Operating Income Loss
OperatingIncomeLoss
-51811000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
22000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
47000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7000
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2461000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
815000
us-gaap Investment Income Interest
InvestmentIncomeInterest
5872000
us-gaap Investment Income Interest
InvestmentIncomeInterest
816000
CY2023Q3 us-gaap Investment Income Dividend
InvestmentIncomeDividend
987000
us-gaap Investment Income Dividend
InvestmentIncomeDividend
1392000
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3866000
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-119000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
5240000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
236000
zura Fair Value Adjustment Of Note Payable
FairValueAdjustmentOfNotePayable
2244000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1383000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1917000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
679000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-279000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20702000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8270000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38778000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-52090000
CY2024Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-20702000
CY2023Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-8270000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-38778000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-52090000
us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
-203000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-20702000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8270000
us-gaap Net Income Loss
NetIncomeLoss
-38778000
us-gaap Net Income Loss
NetIncomeLoss
-51887000
CY2024Q3 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
2240000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
4577000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
203000
zura Deemed Dividend To Redeemable Noncontrolling Interest
DeemedDividendToRedeemableNoncontrollingInterest
10875000
zura Temporary Equity Redemption Value To Carrying Value Adjustment
TemporaryEquityRedemptionValueToCarryingValueAdjustment
7017000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22942000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8270000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-36338000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-62965000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.52
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.52
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.22
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
87335667
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
87335667
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46876344
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46876344
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69778401
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69778401
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28402487
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28402487
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
158063000
CY2024Q3 zura Stock Issued Transaction Costs
StockIssuedTransactionCosts
200000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
626000
CY2024Q3 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-318000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8646000
CY2024Q3 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
2240000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-20702000
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
154587000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
70448000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2577000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8270000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
64755000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
60871000
CY2024Q2 zura Stock Issued Transaction Costs
StockIssuedTransactionCosts
200000
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
626000
us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-318000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13981000
zura Temporary Equity Redemption Value To Carrying Value Adjustment
TemporaryEquityRedemptionValueToCarryingValueAdjustment
7017000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
4577000
us-gaap Net Income Loss
NetIncomeLoss
-38778000
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
154587000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-32056000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
14686000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
4000000.0
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
48351000
zura Stock Issued During Period Value Research And Development License Consideration Liability
StockIssuedDuringPeriodValueResearchAndDevelopmentLicenseConsiderationLiability
4488000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2001000
zura Stock Issued Transaction Costs
StockIssuedTransactionCosts
9800000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10665000
us-gaap Net Income Loss
NetIncomeLoss
-51887000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
203000
zura Value Of Issued Call Right
ValueOfIssuedCallRight
1541000
zura Adjustment Of Deemed Dividend To Redeemable Noncontrolling Interest
AdjustmentOfDeemedDividendToRedeemableNoncontrollingInterest
10875000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
64755000
CY2024Q3 zura Exchange Ratio For Ordinary Shares Pursuant To Business Combination
ExchangeRatioForOrdinarySharesPursuantToBusinessCombination
108.083
us-gaap Profit Loss
ProfitLoss
-38778000
us-gaap Profit Loss
ProfitLoss
-52090000
zura Research And Development Expense On Acquired License
ResearchAndDevelopmentExpenseOnAcquiredLicense
27381000
zura Anti Dilution Share Issuance Compensation
AntiDilutionShareIssuanceCompensation
2186000
us-gaap Share Based Compensation
ShareBasedCompensation
13981000
us-gaap Share Based Compensation
ShareBasedCompensation
5075000
zura Fair Value Adjustment Of Note Payable
FairValueAdjustmentOfNotePayable
2244000
zura Increase Decrease In Research And Development License Consideration Liability
IncreaseDecreaseInResearchAndDevelopmentLicenseConsiderationLiability
1854000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
5240000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
236000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
31000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-6000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-283000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
524000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2049000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2631000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17252000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11001000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
30000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
5000000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
8000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5030000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8000000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
38000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
56683000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
10000000
zura Payment Of Deferred Transaction Costs
PaymentOfDeferredTransactionCosts
52000
zura Payment Of Deferred Transaction Costs
PaymentOfDeferredTransactionCosts
1184000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
110697000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
121293000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
88415000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
102292000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
99806000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1567000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
188221000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
103859000
us-gaap Stock Issued1
StockIssued1
6230000
zura Temporary Equity Redemption Value To Carrying Value Adjustment Non Cash Activities
TemporaryEquityRedemptionValueToCarryingValueAdjustmentNonCashActivities
7017000
us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
4577000
zura Unpaid Transaction Costs
UnpaidTransactionCosts
588000
zura Restricted Share Units Withheld To Pay Employee Withholding Taxes
RestrictedShareUnitsWithheldToPayEmployeeWithholdingTaxes
318000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
18000
zura Accrued License Consideration
AccruedLicenseConsideration
10000000
zura Adjustment Of Deemed Dividend To Redeemable Noncontrolling Interest
AdjustmentOfDeemedDividendToRedeemableNoncontrollingInterest
10875000
zura Issuance Of Shares For Consideration License
IssuanceOfSharesForConsiderationLicense
7840000
zura Conversion Of Series One Convertible Preferred Shares For Ordinary Shares
ConversionOfSeriesOneConvertiblePreferredSharesForOrdinaryShares
14686000
zura Share Based Equity Issuance Costs
ShareBasedEquityIssuanceCosts
5590000
zura Settlement Of Research And Development License Consideration Liability
SettlementOfResearchAndDevelopmentLicenseConsiderationLiability
4488000
zura Assumption Of Public And Private Placement Warrants In Connection With Business Combination
AssumptionOfPublicAndPrivatePlacementWarrantsInConnectionWithBusinessCombination
3715000
zura Reclassification Of Deferred Transaction Costs To Additional Paid In Capital
ReclassificationOfDeferredTransactionCostsToAdditionalPaidInCapital
4015000
zura Reclassification Of Public Warrant Liability To Equity
ReclassificationOfPublicWarrantLiabilityToEquity
2001000
zura Issuance Of Call Right To Noncontrolling Interest
IssuanceOfCallRightToNoncontrollingInterest
1541000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions reflected in the condensed consolidated financial statements relate to and include, but are not limited to, the fair value of Class A Ordinary Shares and other assumptions used to measure share-based compensation, the fair value of redeemable noncontrolling interest, and the fair value of public and private placement warrants.</p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12744621
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22704478
zura Fair Value Liability Level1 To Level2 Transfers Amount
FairValueLiabilityLevel1ToLevel2TransfersAmount
0
CY2024Q3 zura Fair Value Liability Level1 To Level2 Transfers Amount
FairValueLiabilityLevel1ToLevel2TransfersAmount
0
zura Gain Or Loss On Remeasurement Of Research And Development License Consideration Liability
GainOrLossOnRemeasurementOfResearchAndDevelopmentLicenseConsiderationLiability
1900000
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
990000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
5240000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
-6230000
CY2024Q3 zura Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
8760000
CY2023Q4 zura Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
6091000
CY2024Q3 zura Accrued2023 Lilly License Costs
Accrued2023LillyLicenseCosts
5000000
CY2023Q4 zura Accrued2023 Lilly License Costs
Accrued2023LillyLicenseCosts
10000000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1014000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2749000
CY2024Q3 zura Accrued Bonus Cost Current
AccruedBonusCostCurrent
1361000
CY2023Q4 zura Accrued Bonus Cost Current
AccruedBonusCostCurrent
1201000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
948000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
150000
CY2024Q3 zura Withholding Taxes Payable Current
WithholdingTaxesPayableCurrent
584000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
577000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
111000
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
18244000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
20302000
CY2023Q1 us-gaap Preferred Stock Convertible Shares Issuable
PreferredStockConvertibleSharesIssuable
267939
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 zura Exchange Ratio For Ordinary Shares Pursuant To Business Combination
ExchangeRatioForOrdinarySharesPursuantToBusinessCombination
108.083
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 zura Number Of Shares Surrendered
NumberOfSharesSurrendered
4000000
CY2024Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
40961492
zura Class Of Warrant Or Right Warrant Exchange Costs
ClassOfWarrantOrRightWarrantExchangeCosts
1600000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8646000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2577000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13981000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7261000
CY2024Q3 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
16200000
CY2023Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
18700000
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001410578-24-001779-index-headers.html Edgar Link pending
0001410578-24-001779-index.html Edgar Link pending
0001410578-24-001779.txt Edgar Link pending
0001410578-24-001779-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
zura-20240930.xsd Edgar Link pending
zura-20240930x10q.htm Edgar Link pending
zura-20240930xex31d1.htm Edgar Link pending
zura-20240930xex31d2.htm Edgar Link pending
zura-20240930xex32d1.htm Edgar Link pending
zura-20240930xex32d2.htm Edgar Link pending
zura-20240930_def.xml Edgar Link unprocessable
zura-20240930_lab.xml Edgar Link unprocessable
zura-20240930x10q_htm.xml Edgar Link completed
zura-20240930_cal.xml Edgar Link unprocessable
zura-20240930_pre.xml Edgar Link unprocessable